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Abstract Cycloprodigiosin hydrochloride (cPrGWHCl) obtained
from a marine bacterium Pseudoalteromonas denitrificans
induces apoptotic cell death in various cancerous cell lines.
cPrGWHCl alone caused a little cytotoxicity in HeLa cells, but it
enhanced the apoptotic process progressively when co-adminis-
tered with tumor necrosis factor (TNF)K. Here we studied the
effect of cPrGWHCl on TNFK-induced activation of the
transcription factor nuclear factor UB (NF-UB). Luciferase gene
reporter assays revealed that cPrGWHCl potently suppressed the
TNFK- and the phorbol myristate acetate-induced activation of
NF-UB. The suppression occurred in the presence of imidazole,
indicating that it was not related to the intracellular acidification
resulting from the intrinsic H+/Cl3 symporter activity of
cPrGWHCl. cPrGWHCl inhibited neither the TNFK-induced
phosphorylation and degradation of inhibitor of nuclear factor-
UB, nor the subsequent nuclear translocation and DNA binding
of NF-UB. cPrGWHCl also suppressed NF-UB-enhanced gene
expression induced by Rac1, Cdc42, MEKK1, inhibitor of
nuclear factor-UK (IKKK), IKKL, and a subunit of NF-UB,
p65. These results indicate that cPrGWHCl suppresses NF-UB-
dependent gene expression through the inhibition of transcrip-
tional activation. ß 2000 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
Tumor necrosis factor (TNF) K is a proin£ammatory cyto-
kine produced by many types of cells such as macrophages
and monocytes. TNFK binds to the TNF receptors (TNFRs),
and its signal is transduced through several TNFR-associated
signal proteins including TNFR-associated death domain pro-
tein (TRADD), Fas-associated death domain protein
(FADD), receptor-interacting protein (RIP) and TNFR-asso-
ciated factor 2 (TRAF2). Among these, TRADD and FADD
recruit caspase-8 which on activation initiates the apoptotic
process and activation of downstream e¡ector caspases, in-
cluding caspase-3 [1^4]. Conversely, the signal from RIP
and TRAF2 induces nuclear factor UB (NF-UB) activation,
which is considered to have survival promoting e¡ects on cells
and counteract the cytotoxicity of TNFK [5^11].
NF-UB is a heterodimer transcription factor composed of
p65 and p50, whose activation is induced by cytokines such as
IL-1 and TNFK as well as proliferative agents such as phorbol
myristate acetate (PMA) and bacterial lipopolysaccharide.
Upon stimulation by these agents, the inhibitor of NF-UB
(IUB)-kinases (IKKK and IKKL) phosphorylate the inhibitory
proteins (IUBs) associated with NF-UB in the cytoplasm. This
is followed by degradation of the phosphorylated IUBs by the
proteasome. Subsequently, NF-UB is translocated into the nu-
cleus and binds to target DNA sequences to induce gene tran-
scription [12,13].
Cycloprodigiosin hydrochloride (cPrGWHCl), a member of
the prodigiosin family, is the red pigment produced by the
marine bacterium Pseudoalteromonas denitri¢cans [14].
cPrGWHCl induces apoptosis in various cancer cell lines in-
cluding rat and human hepatocellular cancer cells, promyelo-
cytic leukemia cells (HL-60), as well as human breast cancer
cells both in vitro and in vivo [15^17]. A similar observation
has been reported recently in that prodigiosin from Serratia
marcescens induces apoptosis in hematopoietic cancer cells
without inducing any cytotoxicity in non-malignant cells
[18]. Although the mechanism underlying this anti-cancer ef-
fect of the prodigiosin family is still unclear, it should be
noted that cPrGWHCl, as well as other prodigiosins, acts as
an H/Cl3 symporter [19^22] which in turn may induce acid-
i¢cation of the cytosol, since Cl3 ions are generally less abun-
dant in the cytosol than in the extracellular milieu. Further-
more, although it is controversial [23], the intracellular
acidi¢cation is thought to be a prerequisite for the apoptotic
process. In fact, it has been demonstrated that cPrGWHCl in-
duces intracellular acidi¢cation concomitantly with the induc-
tion of apoptosis in cancer cells [15,16]. In addition,
cPrGWHCl-induced apoptosis is potently suppressed by a
membrane permeable weak base imidazole which reverses
the intracellular acidi¢cation [15,16]. Thus, it is most plausible
that the apoptotic e¡ect of cPrGWHCl in these cancer cells is
caused by acidi¢cation of the cytosol. However, not all of the
biological e¡ects of cPrGWHCl are related to acidi¢cation of
the cytosol, since cPrGWHCl induces the di¡erentiation of HL-
60 cells into monocytes, even in the presence of imidazole [16].
Thus, cPrGWHCl modulates cell physiology through intracel-
lular pH modi¢cation and/or unknown molecular target(s).
cPrGWHCl and its related compounds can also act as immu-
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nosuppressants which are selective inhibitors of T cell prolif-
eration [14]. Since cPrGWHCl-induced apoptosis in the human
T cell derived Jurkat cell line, the apoptotic process is possibly
involved in its immunosuppressive e¡ect [14]. It is intriguing
that a cPrGWHCl-related compound, PNU156804, suppresses
the activation of both NF-UB and AP-1 in primary cultured
human T cells [24]. Although the mechanism by which
PNU156804 suppresses NF-UB activation is not clear, these
results suggest that the suppression of NF-UB is involved in its
immunosuppressive activity. This raises the question as to
whether a prodigiosin family compound, cPrGWHCl, also
modulates NF-UB activity in the cells. Here we examined
the e¡ect of cPrGWHCl on the signalling pathway of TNFK,
and found that cPrGWHCl suppressed the gene expression
mediated by NF-UB.
2. Materials and methods
2.1. Materials
The plasmids, pRKF-IKKK and pRKHA-IKKL, have been de-
scribed previously [25]. pRKF-IKKKEE and pRKHA-IKKLEE en-
code constitutively active mutants of IKKK, in which 176 and 180
serine residues in an activation loop are replaced by glutamic acid
residues, and IKKL, in which 177 and 181 serine residues are replaced
by glutamic acid residues, respectively. A reporter plasmid pIG3Luc
for NF-UB encodes triple NF-UB-binding site sequences (AGCTTCA-
GAGGGGACTTTCCGAGAGG) followed by the luciferase gene. A
control plasmid, pBKRLuc, was obtained from Toyobo (Toyo B-Net
Co., Japan). pcDNAF-MEKK1, pRKF-p65, pEFBOSHA-Rac1-DA,
and pEFBOSHA-Cdc42-DA, are the expression plasmids for
MEKK1, the NF-UB subunit p65, constitutively active Rac1 and
Cdc42, respectively. Anti-p50 and anti-p65 antibodies were obtained
from Upstate Biotechnology (Lake Placid, NY, USA). Anti-IUBK
antibody was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA).
2.2. Cell culture
HeLa cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% fetal bovine serum and 50 Wg/ml kanamycin
at 37‡C in 5% CO2 in air.
2.3. Assay for apoptotic processes
Cell viability was determined by dye exclusion assay using 0.1%
trypan blue. DNA fragmentation was analyzed as described previ-
ously [14]. In the caspase-3 assay, cells were disrupted by freeze^
thaw in an extraction bu¡er (50 mM Tris^HCl, pH 7.4, 1 mM
EGTA, 5 mM EDTA, 5 mM MgCl2, 1 mM APMSF, 10 Wg/ml pep-
statin, 10 Wg/ml leupeptin, and 1 mM DTT). Then the suspension was
centrifuged at 15 000 rpm for 20 min, and the supernatants obtained
were incubated at 37‡C for 60 min in a reaction bu¡er (50 mM Tris^
HCl, pH 7.4, 1 mM EDTA, 10 mM EGTA) with 20 WM of the
£uorogenic substrate DEVD-AFC (Peptide Institute, Inc., Japan).
Cleavage of the substrates was quanti¢ed by measuring the £uores-
cence of 7-amino-4-tri£uoromethyl coumarin released using a spectro-
£uorometer (Shimadzu RF5000) with excitation at 380 nm and emis-
sion at 460 nm.
2.4. Luciferase gene reporter assay and kinase assays of IKK
HeLa cells were transfected with the reporter plasmids described
above using Lipofectin (Gibco BRL). After 24^48 h, the luciferase
activity was determined using the luciferase assay system (Promega).
The kinase activity of IKKK and IKKL were analyzed by immune
complex kinase assay as described previously using GST-IUBK (1^55)
as a substrate [25].
Fig. 1. cPrGWHCl induces apoptosis in TNFK-stimulated HeLa cells. A: (Upper panel) HeLa cells were cultured in the presence or absence of
TNFK (20 ng/ml) with or without cPrGWHCl (1 WM) for 18 h. The viable cells were counted by trypan blue exclusion assay. (Lower panel)
Soluble DNA was extracted from HeLa cells cultured in the presence or absence of TNFK (20 ng/ml) supplemented with or without cPrGWHCl
(1 WM) for 24 h. Each soluble DNA sample (20 Wg) was analyzed by electrophoresis on an agarose gel. B: HeLa cells were cultured in the
presence or absence of TNFK (20 ng/ml) supplemented with or without cPrGWHCl (1 WM) for 8 h. Caspase-3 activity was estimated by using
£uorogenic peptides.
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2.5. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared by the method of Schreiber, et al.
[26]. Brie£y, cells were solubilized with a bu¡er (10 mM HEPES^
NaOH, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
0.4% NP-40, 0.5 mM PMSF, 1 Wg/ml aprotinin, 1 Wg/ml leupeptin,
1 Wg/ml pepstatin, 1 mM DTT), and then centrifuged at 10 000 rpm
for 15 min. The pellets were resuspended in a bu¡er (20 mM HEPES^
NaOH, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
PMSF, 1 Wg/ml aprotinin, 1 Wg/ml leupeptin, 1 Wg/ml pepstatin, 1 Wg/
ml chymostatin, 1 Wg/ml antipain, 1 mM DTT), and then centrifuged
at 15 000 rpm for 15 min. The supernatant was used as the nuclear
extract. 32P-labeled DNA probes of the NF-UB-binding site (AGCTT-
Fig. 2. cPrGWHCl suppresses NF-UB-dependent gene expression without suppressing TNFK-induced IUB degradation or the DNA binding of
NF-UB. A: HeLa cells were transfected with pIG3Luc, which contained three NF-UB-binding sites upstream of the luciferase gene. After 24 h,
the cells were treated with cPrGWHCl at various concentrations for 1 h before stimulation with TNFK (20 ng/ml). Following 4 h incubation
with TNFK, NF-UB activity was measured by the luciferase assay. The luciferase activity was normalized by the protein content in each sample.
The results are the mean of duplicate experiments. B: HeLa cells were transfected with pBKRLuc, which encoded the luciferase gene under the
control of the CMV promoter. After 24 h, the cells were treated with or without cPrGWHCl (1 WM) for 5 h, and luciferase activity was mea-
sured. C: HeLa cells were transfected with pIG3Luc. After 24 h, the cells were treated with cPrGWHCl in the presence or absence of imidazole
(10 mM) or ba¢lomycin (1 WM) for 1 h, and then were stimulated by TNFK (20 ng/ml) for 5 h. The results of the luciferase assay are pre-
sented as mean þ S.D. from three independent experiments. D: The cells were transfected with pRKF-IKKK or pRKHA-IKKL. After 24 h, the
cells were treated with cPrGWHCl (1 WM) for 1 h, and then were stimulated by TNFK (20 ng/ml) for 10 min. The transfected IKKK or IKKL
were recovered by immunoprecipitation, and the kinase activity was estimated using GST-IUBK (1^55) as a substrate. E: The cells were pre-
treated with cPrGWHCl (1 WM) for 1 h, and then were stimulated by TNFK (20 ng/ml). The phosphorylation and degradation of IUBK were an-
alyzed by Western blotting using anti-IUB antibody. The black arrow heads indicate IUBK, and the white arrow heads indicate phosphorylated
IUBK. F: Nuclear extracts were prepared from the cells treated with TNFK (20 ng/ml) for 30 min in the presence or absence of cPrGWHCl
(1 WM) or zLLLH (10 WM). Nuclear translocation of p65 and p50 was analyzed by Western blotting. G: DNA-binding activity of NF-UB in
the nuclear extract was analyzed by EMSA. n.s. means a non-speci¢c binding.
FEBS 25341 11-10-01
K. Kamata et al./FEBS Letters 507 (2000) 74^8076
CAGAGGGGACTTTCCGAGAGGTCGA) were prepared as de-
scribed previously [27]. The nuclear extract (10 Wg of protein) was
incubated with the 32P-labeled probes (100 000 cpm) in 20 Wl of bu¡er
(20 mM HEPES^NaOH, pH 7.9, 5% glycerol, 1 mM EDTA, 100 Wg/
ml poly(dI-dC)) for 20 min at room temperature. The samples were
electrophoresed on an 8% polyacrylamide gel and analyzed by an
Imaging plate (Fuji Film).
2.6. Western blot analysis
Cells were solubilized with a bu¡er (20 mM Tris^HCl, pH 7.4, 10
mM EGTA, 10 mM MgCl2, 1 mM benzamidine, 60 mM L-glycero-
phosphate, 1 mM Na3VO4, 20 mM NaF, 1 mM APMSF, 50 u/ml
aprotinin, 20 Wg/ml pepstatin, 20 Wg/ml leupeptin, 1 mM DTT, and
1% Triton X-100), and then centrifuged at 15 000 rpm for 20 min. The
supernatants were used as the cell extracts. The cell extracts and the
nuclear extracts were subjected to SDS^polyacrylamide gel electro-
phoresis, and transferred to an ECL membrane (Amersham Pharma-
cia). Western blot analysis was performed using a Western blotting
detection system (Amersham-Pharmacia) according to the manufac-
turer’s instructions.
3. Results
3.1. cPrGWHCl induces apoptosis in TNFK-stimulated
HeLa cells
We have reported previously that cPrGWHCl induces apo-
ptosis in PMA-stimulated Jurkat cells as well as in various
human cancer cell lines [14,15,17]. In HeLa cells, cPrGWHCl
alone caused relatively little cytotoxicity, while the viability
was reduced to less than 65% of control when cells were
treated by cPrGWHCl together with TNFK (Fig. 1A). DNA
fragmentation was observed in these co-stimulated cells and,
consistent with this, cPrGWHCl activated caspase-3 in cells
treated with TNFK (Fig. 1B). Thus, cPrGWHCl potentiates
the TNFK-induced activation of caspase-3, and enhances the
apoptotic process. Although treatment of HeLa cells with
TNFK alone increased the activity of caspase-3, there was
no loss in the cell viability (Fig. 1A,B).
3.2. cPrGWHCl suppresses TNFK- and PMA-induced activation
of NF-UB without attenuating upstream cellular signalling
pathways
It has been shown that TNFK activates NF-UB, which in
turn leads to the expression of certain genes, such as the in-
hibitor of apoptosis (IAP), to promote cell survival. Indeed,
the suppression of NF-UB results in the potentiation of TNFK
cytotoxicity [6,7,10,11]. This prompted us to study the e¡ect
of cPrGWHCl on activation of NF-UB activation. The cells
were pre-treated with cPrGWHCl for 1 h to exhibit inhibitory
e¡ects on NF-UB activation and the cellular signalling of
TNFK, if any. The luciferase gene reporter assay revealed
that cPrGWHCl suppressed the gene expression dependent on
TNFK-induced NF-UB activation in a dose-dependent manner
(Fig. 2A). As a control, cPrGWHCl completely failed to a¡ect
the expression of the luciferase gene under the control of the
CMV promoter in the reporter assay using a control vector,
pBKRLuc (Fig. 2B). It was intriguing that cPrGWHCl also
inhibited NF-UB transcription activity, even in the presence
of the cell permeable weak base imidazole. This indicated that
the suppression was not a consequence of the intracellular
acidi¢cation due to the intrinsic H/Cl3 symporter activity
of cPrGWHCl (Fig. 2C). A vacuolar-type ATPase inhibitor,
ba¢lomycin, which is also known to induce intracellular acid-
i¢cation, did not suppress NF-UB activation (Fig. 2C). Thus,
the inhibitory e¡ect of cPrGWHCl on NF-UB is not a result of
intracellular acidi¢cation.
TNFK activates NF-UB through the activation of IKKK
and IKKL, phosphorylation and degradation of IUB, and nu-
clear translocation of NF-UB. To determine which step is in-
hibited by cPrGWHCl, we analyzed the e¡ects of this com-
pound on the TNFK signalling systems. When cells were
stimulated with TNFK, both IKKK and IKKL were markedly
activated either in the presence or absence of cPrGWHCl, in-
dicating that cPrGWHCl did not inhibit the signalling from the
TNFr to IKKK and IKKL (Fig. 2D). Consistent with the
activation of IKKK and IKKL, the phosphorylation of IUB
was rapidly induced within 5 min in the presence or absence
of cPrGWHCl as revealed by a mobility shift of electrophoresis
(Fig. 2E). After 30 min, the phosphorylated IUB was degraded
by proteasome, and this degradation was e¡ectively sup-
pressed by a proteasome inhibitor, zLLLH. In contrast,
cPrGWHCl did not inhibit the degradation of the phosphory-
lated IUB. Although the degradation of IUB was una¡ected by
cPrGWHCl, it should be noted that the re-synthesis of IUB after
60 min of TNFK stimulation was potently suppressed by
cPrGWHCl. This is consistent with the observation that the
induction of the IUB gene by extracellular stimuli following
IUB degradation is mediated by NF-UB-dependent gene ex-
pression. The suppression of the re-synthesis of IUB in the
Fig. 3. cPrGWHCl suppresses PMA-induced NF-UB activation. A:
HeLa cells were transfected with pIG3Luc. After 24 h, the cells
were treated with cPrGWHCl at various concentrations for 1 h before
stimulation with PMA (1 WM). Following 4 h incubation with
PMA, NF-UB activity was measured by the luciferase assay. The lu-
ciferase activity was normalized by the protein content in each sam-
ple. B: Nuclear extracts were prepared from the cells treated with
PMA for 30 min in the presence or absence of cPrGWHCl (1 WM).
The nuclear translocation and the DNA-binding activity of NF-UB
were analyzed by EMSA. n.s. means a non-speci¢c binding.
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presence of cPrGWHCl re£ects the blockage of NF-UB activa-
tion.
We next examined the e¡ect of cPrGWHCl on the nuclear
translocation of NF-UB. Nuclear extracts were prepared from
cells stimulated with TNFK in the presence or absence of
cPrGWHCl, and were analyzed by Western blotting with anti-
bodies against the NF-UB subunits, p65 and p50 (Fig. 2F).
TNFK treatment increased the amount of both p65 and p50 in
the nuclear extracts. zLLLH severely reduced the transloca-
tion of both subunits, as expected. In contrast, cPrGWHCl had
no e¡ect on the TNFK-induced increase of p65 and p50 in
nuclear extracts, indicating that the nuclear translocation of
NF-UB was not inhibited by cPrGWHCl. Consistent with these
results, EMSA assays revealed that cPrGWHCl failed to inhibit
the DNA binding of NF-UB in response to TNFK treatment
(Fig. 2G). In addition, cPrGWHCl did not inhibit the DNA
binding of NF-UB in vitro (data not shown).
PMA, is also known to activate NF-UB. As shown in Fig. 3,
although cPrGWHCl did not suppress the nuclear translocation
and the DNA binding of p65, cPrGWHCl again inhibited
PMA-induced NF-UB activation in a dose-dependent manner
similar to the inhibition of TNFK-induced NF-UB activation
by cPrGWHCl. Thus, cPrGWHCl also inhibited speci¢cally the
PMA-induced transcriptional activation by NF-UB.
3.3. cPrGWHCl suppresses the NF-UB-dependent gene
expression induced by Rac1, Cdc42, MEKK1, IKKK,
IKKL and p65
It is of particular interest to determine if cPrGWHCl sup-
presses the transcriptional activity of NF-UB. To address
this point, we transfected the cells with a reporter plasmid
of NF-UB together with an expression plasmid encoding either
the constitutively active mutants, IKKKEE and IKKLEE, or
p65. As shown in Fig. 4A, NF-UB activity was enhanced more
Fig. 4. cPrGWHCl suppresses IKKKEE-, IKKLEE-, p65-, Rac1-, Cdc42- and MEKK1-induced NF-UB transcriptional activity. HeLa cells were
transfected with (A) pRKF-IKKKEE, pRKHA-IKKLEE, pRKF-p65, (B) pEFBOSHA-Rac1-DA, pEFBOSHA-Cdc42-DA, or pcDNAF-
MEKK1 together with the reporter plasmid pIG3Luc and pBKRLuc. After 24 h, the cells were cultured in the presence or absence of
cPrGWHCl (1 WM) or zLLLH (10 WM) for 6 h. NF-UB Activity was measured by the luciferase assay using dual assay kit. The results are pre-
sented as mean þ S.D. from three independent experiments.
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than 5-fold in cells expressing either IKKKEE or IKKLEE,
and more than 8-fold in cells over-expressing p65. zLLLH
partially but signi¢cantly suppressed the IKKKEE- or IK-
KLEE-induced activation of NF-UB. Since zLLLH was added
after the transfection followed by an incubation period re-
quired for the expression of IKKKEE and IKKLEE genes,
NF-UB was already fully activated and hence the inhibition
by zLLLH was apparently partial. cPrGWHCl reduced the
IKKWEE- or IKKLEE-induced activation of NF-UB more po-
tently than zLLLH. Furthermore, cPrGWHCl markedly sup-
pressed the NF-UB-dependent gene expression in cells over-
expressing p65. We further analyzed the e¡ects of cPrGWHCl
on NF-UB in the cells transfected with an expression plasmid
encoding either the constitutively active mutants Rac1 and
Cdc42, or MEKK1, which are also known to activate NF-
UB [28^30]. cPrGWHCl again markedly suppressed the Rac1-,
Cdc42-, and MEKK1-induced activation of NF-UB (Fig. 4B).
Combining these results, it is obvious that cPrGWHCl sup-
presses NF-UB activation at the transcriptional level rather
than at the upstream cellular signalling pathways.
4. Discussion
Here we demonstrated that cPrGWHCl alone caused rela-
tively little cytotoxicity in HeLa cells. However, it enhanced
TNFK-induced apoptosis, suggesting that cPrGWHCl progres-
sively enhances the apoptotic process by suppressing the tran-
scriptional activity of NF-UB. It should be noted that
cPrGWHCl suppressed TNFK-induced NF-UB activation not
only in HeLa cells but also in human astrocytoma U373 cells
(data not shown). Furthermore, cPrGWHCl inhibited NF-UB
activation induced by PMA not only in HeLa cells but also in
U373 cells and COS7 cells (data not shown), indicating that
the suppressive e¡ect on NF-UB is ubiquitous. It has been
reported that PNU156804, an analogue of prodigiosin 25-C,
blocks IL-2-dependent proliferation by suppressing NF-UB
activation in primary cultured human T-lymphocytes [24].
An apparent di¡erence is that the inhibition of NF-UB by
PNU156804 was due to the attenuation of IUBK and IUBL
degradation speci¢cally in human lymphocytes, whereas
cPrGWHCl inhibits neither the degradation of IUBK nor the
concomitant nuclear translocation and DNA binding of NF-
UB. Although the di¡erence in the mechanism of the inhibi-
tory action between cPrGWHCl and PNU156804 in these cell
types is unclear, it is obvious that prodigiosin family com-
pounds act as inhibitors of NF-UB activation in response to
a wide range of extracellular stimuli in various cell types.
So far, several inhibitors of NF-UB activation have been
reported. Among them, anti-in£ammatory agents such as as-
pirin [31,32], sodium salicilate [33], and an indomethacin-re-
lated sulindac [34] are known to suppress NF-UB-dependent
gene expression. Also, various natural products such as pros-
taglandin [35], curcumin [36], capcisin [37], and silymarin [38]
are inhibitors of NF-UB activity. These agents preferentially
reduce IUB degradation by inhibiting IKK activity and/or by
attenuating the cellular signalling system linked to NF-UB
activation. Furthermore, arsenite [39] and thiol metal com-
pounds such as aurano¢n [40] directly inhibit IKK activity
thereby suppressing NF-UB activation. In this context, the
mode of action of cPrGWHCl is clearly di¡erent from that of
these inhibitors since the TNFK-induced IUB degradation and
IKK kinase activity are not a¡ected by cPrGWHCl as shown in
Fig. 2D,E. Rather, our study indicated that cPrGWHCl sup-
pressed NF-UB-mediated gene expression without attenuating
upstream signalling pathways.
In contrast, it has been revealed that several molecules sup-
press NF-UB-enhanced gene expression without inhibiting
IKK activity, IUB phosphorylation, or the nuclear transloca-
tion of p65. Among them, a class of pyridinyl imidazoles,
SB203580, suppresses NF-UB-dependent gene transcription
by inhibiting p38 MAP kinase which phosphorylates TFIID
(TATA-binding protein, TBP) [41]. This is also clearly di¡er-
ent from the action of cPrGWHCl since cPrGWHCl did not
inhibit p38 MAP kinase (data not shown). Conversely. both
an immunosuppressant PG490 (Triptolide) [42] and chromium
(VI) [43] inhibit the transcriptional activation by NF-UB in the
absence of inhibition of nuclear translocation and DNA bind-
ing, indicating that these inhibitors act on the transcriptional
machinery of NF-UB. The characteristics of inhibition by
cPrGWHCl suggest that this compound also acts on the tran-
scriptional step(s), resulting in the suppression of NF-UB-de-
pendent gene expression.
Although it is still unclear how cPrGWHCl suppresses the
transcriptional activation by NF-UB, our results allow the
proposal of several plausible target(s) of cPrGWHCl. When
NF-UB binds to the DNA target sequence, the p65 subunit
recruits transcriptional coactivator molecules, such as the
cAMP response element-binding protein (CBP) and p300,
and general transcription factors such as RNA polymerase
II [44,45]. Furthermore, it has been reported that LPS induces
protein kinase A-dependent phosphorylation of p65 at serine
276 residue in T and B cell lines [46], of which phosphoryla-
tion leads to the recruitment of CBP and p300 [47]. As
cPrGWHCl does not inhibit the transcription of the luciferase
reporter gene under the control of the CMV promoter (Fig.
2B), the activities of general transcription factors are not sup-
pressed by cPrGWHCl. Rather, it is more plausible that
cPrGWHCl interferes with the speci¢c interaction between
p65 and these transcriptional coactivators or general tran-
scription factors. Alternatively, cPrGWHCl possibly suppresses
the activity of transcriptional factors associated with NF-UB.
Suppression of NF-UB activity severely disturbs the immune
system, and also suppresses cell transformation, and we have
observed that cPrGWHCl acts as an immunosuppressant and
an anti-tumor drug. We conclude that the suppression of NF-
UB by cPrGWHCl might confer the immunosuppressant and
anti-tumor e¡ects of this prodigiosin molecule.
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